Immuneering’s Promising Phase 2a Data and Safety Profile Drive Buy Rating
I'm PortAI, I can summarize articles.
Ami Fadia has issued a Buy rating for Immuneering, citing promising Phase 2a data for atebimetinib in treating pancreatic ductal adenocarcinoma (PDAC). The median progression-free survival of 9.6 months surpasses daraxonrasib's 8.1 months, with atebimetinib showing a superior safety profile. This could enhance treatment durability and make it a preferred first-line option. Fadia, a 5-star analyst, has an average return of 13.2% and a 49.89% success rate. Piper Sandler also maintains a Buy rating with a $12.00 price target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments